INCB186748 + cetuximab

INCB186748 + cetuximab is a combination investigational therapy being studied for the treatment of advanced or metastatic solid tumors harboring a KRAS G12D mutation. INCB186748 is a novel oral small molecule designed to selectively inhibit the KRAS G12D mutant protein, which is a common driver mutation in several cancers including pancreatic and colorectal cancer. Cetuximab is a monoclonal antibody targeting the Epidermal Growth Factor Receptor (EGFR), blocking EGFR signaling pathways involved in cell proliferation and survival. The combination aims to simultaneously inhibit mutant KRAS-driven tumor growth and disrupt EGFR-mediated signaling, potentially overcoming resistance mechanisms and enhancing antitumor activity in solid tumors. The therapy is currently under evaluation in phase I clinical trials for safety, tolerability, and preliminary efficacy in these patient populations[1][2][3][4][7][10].

Other names

INCB-186748INCB186748INCB 186748